Video Webinar, presented by the Bayh-Dole Coalition and ITIF
Bayh-Dole’s “march-in” provision — which allows the government to mandate the relicensing of federally-funded innovations in limited circumstances — is often subject to misinterpretation. For nearly 20 years, critics have claimed that Bayh-Dole’s march-in right can be used as a price-setting mechanism — rather than a tool meant to ensure that private companies make good faith efforts to commercialize federally-funded inventions.
This video webinar, co-hosted by the Bayh-Dole Coalition and ITIF, clarifies the provision’s intent and explains once and for all how Bayh-Dole’s march-in right can and cannot be used. Speakers detail how misusing march-in rights as a price-setting mechanism would eliminate research, development, and investment incentives across the technology transfer, venture capital, and life sciences industries.
Articles cited during the webinar include:
Executive Director, Bayh-Dole Coalition
Former President, National Technology Transfer Center
President, Council on Governmental Relations (COGR)
Former Executive Director of Research Policy Analysis and Coordination, University of California
Former Associate Director of Technology Transfer, Auburn University
President and Chair of the Board, LES (USA & Canada)
Special Counsel for Innovation and Government Collaborations, GSK Vaccines
Former VP, Associate General Counsel & Chief Intellectual Property Counsel, Emergent BioSolutions Inc.,